Antibody-based therapeutics: Focus on prostate cancer

Cancer and Metastasis Reviews

Volumn 24, Issue 4, 2005, Pages 521-537

  Ross, Jeffrey S ^a,b   Gray, Karen E ^c   Webb, Iain J ^a   Gray, Gary S ^a   Rolfe, Mark ^a   Schenkein, David P ^a   Nanus, David M ^d   Millowsky, Mathew I ^d   Bander, Neil H ^d  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c Veridex LLC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibody therapeutics; Bevacizumab; Cetuximab; EGFR; Hepsin; MUC1; Prostate cancer; PSCA; PSMA; Review; Trastuzumab

Indexed keywords

'DM 1'; ALEMTUZUMAB; ANTHRACYCLINE; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CETUXIMAB; DACLIZUMAB; DOCETAXEL; EDRECOLOMAB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MAYTANSINE; MDX 070; MDX 210; MLN 2704; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E99; MONOCLONAL ANTIBODY J415; MONOCLONAL ANTIBODY J533; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 IN 111; MONOCLONAL ANTIBODY J591 LU 177; MONOCLONAL ANTIBODY J591 Y 90; PROSTATE STEM CELL ANTIBODY; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ASTHMA; B CELL LYMPHOMA; BLEEDING; BLOOD TOXICITY; BYSTANDER EFFECT; CANCER; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG TARGETING; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY DIAGNOSIS; LEUKEMIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIPLE SCLEROSIS; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MODIFICATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; TARGET CELL; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TOXICITY; ULCERATIVE COLITIS; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; IMMUNIZATION, PASSIVE; MALE; PROSTATIC NEOPLASMS;

EID: 30744448189     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-005-6194-0     Document Type: Review

References (98)

1. Reilly RM, Sandhu J, Alvarez-Diez TM, et al.: Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 28: 126-142, 1995
2. Winter G, Harris WJ: Humanized antibodies. Immunol Today 14: 243-246, 1993
3. Merluzzi S, Figini M, Colombatti A, et al.: Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path 4: 77-85, 2000
4. Kuus-Reichel K, Grauer LS, Karavodin LM, et al.: Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1: 365-372, 1994
5. Pimm MV: Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: A note of caution. Life Sci 55: PL45-PL49, 1994
6. Jones PT, Dear PH, Foote J, et al.: Replacing the complementarity- determining regions in a human antibody with those from a mouse. Nature 321: 522-525, 1986
7. Isaacs JD: From bench to bedside: Discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology 40: 724-738, 2001
8. Watkins NA, Ouwehand WH: Introduction to antibody engineering and phage display. Vox Sang 78: 72-79, 2000
9. Reff ME, Hariharan K, Braslawsky G: Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 9: 152-166, 2002
10. Chester KA, Hawkins RE: Clinical issues in antibody design. Trends Biotechnol 13: 294-300, 1995
11. Reff ME, Heard C: A review of modifications to recombinant antibodies: Attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 40: 25-35, 2001
12. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975
13. Carter P: Improving the efficacy of antibody-based cancer therapies. Nature Rev Cancer 1: 118-129, 2001
14. Goldenberg DM: Targeted therapy of cancer with radio-labeled antibodies. J Nucl Med 43: 693-713, 2002
15. Reichert JM: Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr Opin Mol Ther 4: 110-118, 2002
16. Reichert JM: Monoclonal antibodies in the clinic. Nat Biotechnol 19: 819-822, 2001
17. Hemminki A: From molecular changes to customised therapy. Eur J Cancer 38: 333-338, 2002
18. Milenic DE: Monoclonal antibody-based therapy strategies: Providing options for the cancer patient. Curr Pharm Des 8: 1749-1764, 2002
19. Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46(Suppl 1): 115S-127S, 2005
20. Bander NH, Nanus DM, Milowsky MI, et al.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 30: 667-676, 2003
21. Ross JS, Jennings TA, Nazeer T, et al.: Prognostic factors in prostate cancer. Am J Clin Pathol 120(Suppl): S85-S100, 2003
22. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-936, 1987
23. Israeli RS, Powell CT, Farr WR, et al.: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-230, 1994
24. Israeli RS, Powell CT, Fair WR, et al.: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994
25. Wright GL Jr, Haley C, Beckett ML, et al.: Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol 1: 18-28, 1995
26. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-558, 1995
27. Sokoloff RL, Norton KC, Gasior CL, et al.: A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. The Prostate 43: 150-157, 2000
28. Bostwick DG, Pacelli A, Blute M, et al.: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 82: 2256-2261, 1998
29. Wright GL Jr, Grob BM, Haley C, et al.: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-334, 1996
30. Sweat SD, Pacelli A., Murphy GP, et al.: PSMA expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52: 637-640, 1998
31. Ross JS, Sheehan CE, Fisher HA, et al.: Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9: 6357-6362, 2003
32. Pinto JT, Suffoletto B, Berzin TM, et al: Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Can Res 2: 1445-1451, 1996
33. Kahn D, Williams RD, Manyak MJ: 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159: 2041-2046, 1998
34. Kahn D, Williams RD, Haseman MK, et al: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16: 284-289, 1998
35. Troyer JK, Feng Q, Beckett ML, et al: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1: 29-37, 1995
36. Troyer JK, Beckett ML, Wright GL, Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30: 232-242, 1997
37. Liu H, Moy P, Kim S, et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634, 1997
38. Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ: The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 20: 211-218, 2002
39. Liu H, Rajasekaran AK, Moy P, et al: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Can Res 58: 4055-4060, 1998
40. McDevitt MR, Barendswaard E, Ma D, et al: An alpha-particle emitting antibody for radioimmunotherapy of prostate cancer. Cancer Res 60: 6095-6100, 2000
41. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60: 5237-5243, 2000
42. Smith-Jones PM, Vallabhajosula S, Navarro V, et al: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nuc Med 44: 610-617, 2003
43. Henry MD, Wen S, Silva MD, et al.: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64: 7995-8001, 2004
44. Bander NH, Nanus D, Bremer S, et al: Clinical trial targeting a monoclonal antibody to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer. Proc Am Soc Clin Oncol 19: 477A, 2000
45. Bander NH, Nanus D, Goldsmith SJ, et al: Phase I trial of humanized monoclonal antibody to prostate specific membrane antigen/extracellular domain. Proc Am Soc Clin Oncol 20: 181a, 2001
46. Nanus DM, Milowsky MI, Kostakoglu L, et al.: Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170(6 Pt 2): S84-S88, 2003
47. Milowsky MI, Nanus DM, Kostakoglu L, et al.: Phase I Trial of Yttrium-90 - Labeled Anti - Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer. J Clin Oncol 22: 2522-2531, 2004
48. Galsky MD, Eisenberger M, Moore-Cooper S, et al.: Phase I trial of MLN2704 in patients with progressive castrate metastatic prostate cancer. Proc Am Soc Clin Oncol 23: 464a, 2004
49. Galsky MD, Eisenberger M, Moore-Cooper S, et al.: Phase 1/2 Dose Escalation trial of the prostate specific membrane antigen (PSMA)-Targeted immunoconjugate, MLN2704, in patients with progressive metastatic androgen-independent prostate Cancer. Proc Am Soc Clin Oncol 24: 2005
50. Chang SS, Reuter VE, Heston WDW, et al.: Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature. Cancer Res 59: 3192-3198, 1999
51. Ross JS, Sheehan CE, Gray K, et al.: Expression of prostate specific membrane antigen in the neovasculature of non-prostate cancers. Proc Am Soc Clin Oncol 23: 222, 2004
52. Gong MC, Chang SS, Sadelain M, et al.: Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev 18: 483-490, 1999
53. Milowsky MI, Rosmarin AS, Cobham MV, et al.: Anti-PSMA mAb HuJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol 21: 29, 2002
54. Amara N, Palapattu GS, Schrage M, et al.: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 61: 4660-4665, 2001
55. Argani P, Rosty C, Reiter RE, et al.: Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 61: 4320-4324, 2001
56. Bahrenberg G, Brauers A, Joost HG, et al.: Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun 275: 783-788, 2000
57. Gu Z, Thomas G, Yamashiro J, et al.: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19: 1288-1296, 2000
58. Ross S, Spencer SD, Holcomb I, et al.: Prostate Stem Cell antigen as therapy target. Cancer Res 62: 2546-2553, 2002
59. Matsueda S, Kobayashi K, Nonaka Y, et al.: Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 53: 479-489, 2004
60. Dannull J, Diener P-A, Prikler L, et al.: Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Research 60: 5522-5528, 2000
61. Ross JS, Fletcher JA: HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112(1 Suppl 1): S53-S67, 1999
62. Huston JS, George AJ: Engineered antibodies take center stage. Hum Antibodies 10: 127-142, 2001
63. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for Metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
64. Osman I, Scher HI, Drobnjak M, et al.: HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7: 2643-2647, 2001
65. Fossa A, Lilleby W, Fossa SD, et al.: Independent prognostic significance of HER-2 oncoprotein expression in pNO prostate cancer undergoing curative radiotherapy. Int J Cancer 99: 100-105, 2002
66. Ross JS, Sheehan C, Hayner-Buchan A, et al.: HER2/neu gene amplification status in prostate cancer by fluorescence in-situ hybridization. Hum Pathol 28: 827-833, 1997
67. Morris MJ, Reuter VE, Kelly WK: HER-2 profiling and targeting in prostate carcinoma. Cancer 94: 980-986, 2002
68. Lara PN Jr, Chee KG, Longmate J, et al.: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100: 2125-2131, 2004
69. Disis ML, Schiffman K: Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28: 12-20, 2001
70. Valone FH, Kaufman PA, Guyre PM, et al.: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13: 2281-2292, 1995
71. Lewis LD, Beelen AP, Cole BF, et al.: The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer. Cancer Chemother Pharmacol 49: 375-384, 2002
72. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000
73. Baselga J: The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37(Suppl 4): S16-S22, 2001
74. Prewett M, Rockwell P, Rockwell RF, et al.: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19: 419-427, 1996
75. Canil CM, Moore MJ, Winquist E, et al.: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the national cancer institute of canada-clinical trials group. Journal of Clinical Oncology 23: 455-460, 2005
76. Ware JL: Prostate cancer progression. Implications of Histopathology. Am J Pathol 145: 983-993, 1994
77. Di Lorenzo G, Tortora G, D'Armiento F, et al.: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002
78. Weidner N, Carroll PR, Flax J, et al.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993
79. Bigler SA, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24: 220-226, 1993
80. Silberman MA, Partin AW, Veltri RW, et al.: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997
81. Brawer MK, Deering RE, Brown M, et al.: Predictors of pathologic stage in prostatic carcinoma. Cancer 73: 678-687, 1994
82. Rosen LS: Angiogenesis inhibition in solid tumors. Cancer J 7(Suppl 3): S120-S128, 2001
83. Rosen LS: Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9(2 Suppl): 36-44, 2002
84. Duque JL, Loughlin KR, Adam RM, et al.: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523-527, 1999
85. Bok RA, Halabi S, Fei DT, et al.: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61: 2533-2536, 2001
86. Fox WD, Higgins B, Maiese KM, et al.: Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8: 3226-3231, 2002
87. Sweeney P, Karashima T, Kim SJ, et al.: Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8: 2714-2724, 2002
88. Picus J, Halabi S, Rini B, et al.: The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 22: 393, 2003
89. Drake MH, Robson W, Mehta P, et al.: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88: 822-827, 2003
90. Figg WD, Arlen P, Gulley J, et al: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28: 62-66, 2001
91. Capitosti SM, Hansen TP, Brown ML: Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. Bioorg Med Chem 12: 327-336, 2004
92. Nelson J, Bagnato A, Battistini B, et al: The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116, 2003
93. Carducci MA, Nelson JB, Bowling K, et al.: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171-2180, 2002
94. Zhang S, Zhang HS, Reuter VE, et al.: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4: 295-302, 1998
95. Kirschenbaum A, Itzkowitz SH, Wang JP, et al.: MUC1 expression in prostate carcinoma: Correlation with grade and stage. Mol Urol 3: 163-168, 1999
96. Chen Z, Fan Z, McNeal JE, et al.: Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 169: 1316-1319, 2003
97. Magee JA, Araki T, Patil S, et al.: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696, 2001
98. Klezovitch O, Chevillet J, Mirosevich J, et al.: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6: 185-195, 2004